Publications Feature VELCADE(R) (Bortezomib) For Injection Strength In Hematological Cancers

Tue, 05 Dec 2006 02:00 PM EST

... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the publication of clinical data of VELCADE in the treatment of newly diagnosed multiple myeloma (MM), MM accompanied by advanced renal failure, and mantle cell lymphoma (MCL). These data underscore the substantial activity and well-characterized safety profile of VELCADE in the treatment of hematological cancers. [click link for full article] ...